Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.34 |
| ▸ | HTR2A | P28223 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | GMNN | O75496 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9504583 | 0.84 | TYR (0.37) | ALOX15KDM4EMEN1ALDH1A1CYP3A4 | |
| SCHEMBL21244767 | 0.78 | KDM4E (0.39) | MAPK14HTR2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL15724412 | 0.78 | HTR2C (0.41) | MAPK11MAPK14HTR2AKDM4EMEN1 | |
| SCHEMBL15723823 | 0.78 | MAPK11 (0.39) | MAPK11MAPK14HTR2ABRD4CREBBP | |
| SCHEMBL15723850 | 0.76 | HTR2C (0.53) | MAPK11MAPK14HTR2ACYP3A4CYP1A2 | |
| SCHEMBL15991500 | 0.74 | SRC (0.37) | ALOX15ALOX12KDM4EMEN1ALDH1A1 | |
| SCHEMBL108453 | 0.72 | PRKCI (0.50) | ACHEMAPTGPR35DAO | |
| SCHEMBL29803376 | 0.72 | PRKCI (0.50) | ACHEMAPTGPR35DAO | |
| SCHEMBL13204941 | 0.72 | HTR2C (0.53) | MAPK11MAPK14HTR2AALDH1A1NR1I2 | |
| SCHEMBL599047 | 0.72 | HTR2A (0.53) | HTR2ACYP1A2SLC6A2MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0335477-B1 | THE USE OF N-SUBSTITUTED-5,6-DIHYDROXYINDOLES AS A HAIR COLORING AGENT | Bristol-Myers Squibb Company (US) | 1993-07-21 | — | — | EP | claimed |
| EP-0335477-A2 | The use of N-substituted-5,6-dihydroxyindoles as a hair coloring agent | Bristol-Myers Squibb Company (US) | 1989-10-04 | — | — | EP | claimed |
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-08-29 | — | — | US | disclosed |
| EP-0637955-A4 | HAIR DYEING COMPOSITIONS COMPRISED OF 5,6-DIHYDROXYINDOLE AND A CHLORITE OXIDANT AND METHODS OF DYEING THEREWITH. | BRISTOL MYERS SQUIBB CO (US) | 1995-11-08 | — | — | EP | disclosed |
| US-5413612-A | Oxidation color dyes for hair and packages | CLAIROL INCORPORATED (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0637955-A1 | HAIR DYEING COMPOSITIONS COMPRISED OF 5,6-DIHYDROXYINDOLE AND A CHLORITE OXIDANT AND METHODS OF DYEING THEREWITH | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-15 | — | — | EP | disclosed |
| WO-1993021898-A1 | HAIR DYEING COMPOSITIONS COMPRISED OF 5,6-DIHYDROXYINDOLE AND A CHLORITE OXIDANT AND METHODS OF DYEING THEREWITH | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-11-11 | — | — | WO | disclosed |
| EP-0335477-B1 | THE USE OF N-SUBSTITUTED-5,6-DIHYDROXYINDOLES AS A HAIR COLORING AGENT | Bristol-Myers Squibb Company (US) | 1993-07-21 | — | — | EP | disclosed |
| EP-0335477-A2 | The use of N-substituted-5,6-dihydroxyindoles as a hair coloring agent | Bristol-Myers Squibb Company (US) | 1989-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190262371-A1 | METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS | POLRMT, EIF2AK2, NSUN3 | ACHE 4595/4885MAPK11 4816/4885MAPK14 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.